193977-34-3

Upstream product

• 129322-83-4 2',4',5'-trifluoroacetophenone 

Downstream Products

• 1033041-27-8 2-(2-iminooxazol-3(2H)-yl)-1-(2,4,5-trifluorophenyl)ethanone hydrobromide 
• 1336804-23-9 C₁₁H₅F₃N₂S 
• 1336804-58-0 NSC 747419 
• 1336804-37-5 C₁₂H₅F₃N₂OS 

Relevant academic research and scientific papers

Synthetic studies connected with the preparation of 4-cyclopropyl-7-fluoro-6-(4-methylpiperazin-1-yl)-1,2,4,9-tetrahydrothiazolo[5, 4-b]quinoline-2,9-dione

Target 4-cyclopropyl-7-fluoro-6-(4-methylpiperazin-1-yl)-1,2,4,9-tetrahydrothiazolo[5, 4-b]quinoline-2,9-dione (5a) was obtained from 3-amino-1-cyclopropyl-6-fluoro-7-(4-methylpiperazin-1-yl)-2-mercaptoquinolin- 4(1H)-one (9b). This intermediate was obtained from 3-amino-1-cyclopropyl-6,7-difluoro-2-(methylsulfinyl)quinolin-4(1H)-one (9f) via 3-amino-1-cyclopropyl-6-fluoro-7-(4-methylpiperazin-1-yl)-2-(methylsulfinyl) quinolin-4(1H)-one (9c). Compound 9f was prepared from 2,4,5-trifluoroacetophenone (6a) in several steps. 4-Cyclopropyl-6,7-difluoro-2,3,4,9-tetrahydrothiazolo[5,4-b]quinoline-3,4-dione (5b) was prepared similarly as the target compound. Treatment of 5b with N-methylpiperazine did not afford 5a but 1-cyclopropyl-6,7-difluoro-2-mercapto-3-[(4-methylpiperazin-1-yl)carbonylamino] quinolin-4(1H)-one (11). Several unsuccessful attempts to prepare compound 5a and/or some useful intermediates of its synthesis are also described.

FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure Formula (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, Z, X, R1, R2 m, p and a are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-β, and can be used to treat disease by blocking TGF-β signaling.

TGF-Beta Inhibitors

Disclosed are imidazole and thiazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, A, Z, R1 and R′ are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-β, and can be used to treat disease by blocking TGF-β signaling.

NOVEL IMIDAZOTHIAZOLES AND IMIDAZOXAZOLES

The present invention is directed to novel compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.